News | Focused Ultrasound Therapy | March 19, 2019

Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System

Focal One ablates only the diseased portion of the prostate

Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System

March 19, 2019 — EDAP TMS SA announced that Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm robotic high intensity focused ultrasound (HIFU) for patients with localized prostate cancer, has acquired the advanced Focal One HIFU technology. Houston Methodist Hospital initially invested in EDAP's first-generation HIFU system, Ablatherm, in early 2016, and within two years of positive experience made the decision to invest in the next-generation Focal One device.

"Each proposal for cutting edge medical technology must demonstrate how a new procedure will benefit patients, how it differs from competing technologies and how it contributes to the hospital's overall growth," said Michael Garcia, senior vice president, operations at Houston Methodist Hospital. "In deciding whether to invest in Focal One, we applied these same due diligence principles that we used in the previous technology evaluations. Following the successful business case that we experienced with Ablatherm, we believe Focal One's capabilities will meet and exceed our expectations."

"Focal One realizes the promise of focal therapy for prostate cancer that has long been anticipated," said Brian Miles, M.D., professor of urology at Houston Methodist's Weill Cornell Medical College, who championed the effort to acquire Focal One. "Just like the lumpectomy has become a standard option for treating breast cancer, we can now use Focal One to ablate only the diseased portion of the prostate when appropriate, rather than removing the prostate altogether."

For more information: www.edap-tms.com

Related Content

The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...
ASTRO urges radiation oncology benefits management company eviCore to reconsider a move that requires shorter treatment regimens without regard for physician judgement

Getty Images

News | Radiation Oncology | October 02, 2020
October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | June 23, 2020
June 23, 2020 — An innovativ...
Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 sc

Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 scan (arrow in C), later verified on pathology as true malignant lesion. Images created by J. Kuten et al., Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

News | Prostate Cancer | May 12, 2020
May 12, 2020 — The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting mali
Richard J. Price, Ph.D., of the University of Virginia's School of Medicine and School of Engineering, is using focused soundwaves to overcome the natural 'blood-brain barrier,' which protects the brain from harmful pathogens. Photo courtesy of Dan Addison | UVA Communications

Richard J. Price, Ph.D., of the University of Virginia's School of Medicine and School of Engineering, is using focused soundwaves to overcome the natural 'blood-brain barrier,' which protects the brain from harmful pathogens. Photo courtesy of Dan Addison | UVA Communications

News | Focused Ultrasound Therapy | May 07, 2020
May 7, 2020 — University of Virginia researchers are pioneering the use of...